1.
Carboplatin, Fluorouracil and L-Folinic Acid in the treatment of
Advanced Squamous Cell Carcinoma of the Head and Neck
(SCCHN)
.
Guaraldi M., Martoni A., Morelli F., Panetta A., Tamberi
S., Pannuti F. Annals of Oncology 5
(suppl.8):123,1994
2.
A phase I-II study on 5-day 5-Fluorouracil continuous infusion with
levo-Folinic Acid modulation in advanced colo-rectal
cancer.
Martoni A., Angelelli B., Panetta A., Tamberi
S., Pannuti F. Proceedings of the "XVI International
Cancer Congress". New Delhi 30 ottobre-5
novembre 1994
3.
Combined chemo-immuno-ormonotherapy of advanced renal cell
carcinoma.
Panetta A., Martoni A., Guaraldi M., Tamberi
S., Casadio M., Lelli G., Pannuti F. Journal of
Chemotherapy 6:5,349-353, 1994
4.
Prevalenza e caratteristiche morfologiche di lesioni polipoidi del
tratto digestivo
superiore
nella poliposi adenomatosa familiare.
Santucci R., Volpe L., Calabrese C., Poggi B., Di Febo G.,
Tamberi S., Biasco G. "I Tumori
gastrici. Bilanci e prospettive" Roma 9-11 novembre 1995
5.
Terapia cronomodulata dei tumori solidi.
Biasco G., Brandi G., Tamberi S. G.Biasco.
"Trials clinici in oncologia". Bologna, 1995
6.
Abnormal mucosal cell proliferation as a biomarker of
gastrointestinal cancer: methodological issues and clinical
applications
Biasco G., G.M.Paganelli, U.Zannoni, G.Brandi, R.Santucci, M.Renga,
P.Mordenti, S.Tamberi, L.Barbara. Journal
of tumor marker oncology vol.10 ,2, pag.89, 1995
7.
Colonization of human achloridric stomach by
Bifidobacteria
Brandi G., Sarchielli S., Mordenti P., Tamberi
S., Calabrese C., Mattarelli P., Biavati B.,
Biasco Gut
1996; 39 (suppl 3), abstr.1392
8.
Cell proliferation of the gastric mucosa: a mechanism of
cytoprotection
Santucci, L. Volpe, B. Poggi, S.Tamberi, P.
Mordenti, G.Biasco in: R.Cheli, G.Iaquinto, S.Szabo (eds):
Gastroduodenal Mucosal Damage: Problems of
protection and
healing, 1997 pp.13-16
9.
Appunti di Oncologia Medica - Tumori solidi.
Biasco G., Tamberi S CLUEB, Bologna
1997
10.
Anti-Candida activity of six essential oils in vitro.
Brandi G., Presenti M., Biasco G., Nannetti A., Santucci R.,
Tamberi S., Moreno S., Miglioli
M., Biavati Bioscience and Microflora 16 (2);p.17,
1997
11.
Is presumable a different type of oral anti-fungal prophylaxis in
neutropenic cancer patients? Anti-Candida
activity of essential oils.
Brandi G., Pesenti M., Biasco G., Nannetti A., Santucci R.,
Tamberi S., Salini L., Pisi
A.M.,Asmelash G., Biavati B.
Proceedings of "8th international congress on
anti-cancer treatment".
Parigi 3-6 febbraio 1998
12.
Prognostic and therapeutic aspects of non-small cell lung
cancer.
Biasco G., Tamberi S.
Proceedings of "II International congress on Thorax
Surgery".
Bologna. 22-24 giugno 1998
13.
Clinical biology of small-cell lung cancer: relationship to medical
treatment
. Biasco G., Tamberi S Proceedings of "II
International congress on Thorax Surgery".
Bologna.22-24 giugno 1998
14.
Trattamento integrato del cancro del retto:
chemio-radioterapia
G.Frezza, S.Tamberi In Il cancro del retto:
problemi di gestione clinica Barbieri E., Biasco G.,
Frezza G.P, Tamberi S.(eds); pag.81-92,
Bologna 1998
15.
After surgery surveillance in high risk colorectal cancer
patients.
Santucci R., Poggi B., Volpe L., Calabrese C., Mordenti P., Brandi
G., Tamberi S., Di Febo G., Miglioli M.,
Biasco G. Annals of Oncology 43, suppl.4: vol.9,
1998
16.
Bimonthly 5-Fluorouracil (FU) and l-Folinic acid (FA) (De Gramont
regimen) in advanced colorectal cancer (ACC): relationship between
toxicity and quality of life (QoL).
Poggi B., Mordenti P., Tamberi S., Baroncini
S., Bonarelli S., Renga M., Biasco G. Tumori 88, suppl.1
vol.84, number 5,1998
17.
Carboplatin (CBDCA) and Paclitaxel (TAX) in advanced non small cell
lung cancer: preliminary results.
Tamberi S.
,
Mordenti P., Poggi B., Di Marco M.C., Casadei S. Bazzocchi R.,
Biasco G. Tumori 93, suppl.1 vol.84, number
5,1998
18.
Subcutaneous Interleukin-2 (IL-2) and alfa-2b-Interferon (IFN) plus
5-Fluorouracil (5-FU) in continuous infusion (CI) in advanced renal
cell carcinoma: a phase II study.
Maltoni R., Casadei S., Tamberi
S., Fabbri M, Vitali P., Biasco G.,
Ridolfi R. Tumori 129, suppl.1 vol.84, number
5,1998
19.
Role of the gut flora (IBF) in the intestinal toxicity from CPT-11
in Mice.
Brandi G., Dabar J., Biasco G., Raibaud P., Bridonneau C., Poggi
B., Pisi A.M.,Tamberi S, Comis S., Tura S.
Proc.ASCO Vol.18,abstr.1068, 1999
20.
Carboplatin (CBDCA) and Paclitaxel (TAX) as induction chemotherapy
in stage IIIA-IIIB non small cell lung cancer.
S.Tamberi
,
E.Gallerani, R.Bazzocchi, M.Zompatori, G.Martinelli, M.Schiavina,
M.C.Di Marco, G.Brandi, G.Biasco Eur J Cancer vol.35, suppl
4, S264, 1999
21.
Oxaliplatin (OHP) in advanced colorectal cancer (ACC): safety and
toxicity
Mordenti P., Poggi B., Casadei S., Di Marco M.C.,
Tamberi S., Bonarelli S., Baroncini S., Biasco
G. Atti de 1° Congresso Nazionale di Oncologia Medica, Roma
24-28 ottobre 1999, pag. 20
22 Preoperative radiation therapy with concurrent 5 Fluorouracil
(5-FU) in continuous infusion in distal rectal cancer: preliminary
results.
S.Tamberi,
N.Minguzzi, E.Emiliani, GP Frezza, D.Cimatti, E.Montanari,
A.Piancastelli, G.Cruciani, M.Marangolo
Annals of Oncology
11 (supll.4), p.53, 2000
23 Efficacy and tolerability of gefitinib in pretreated elderly
patients with advanced non – small cell lung cancer.
Cappuzzo F., Bartolini S., Cresoli GL., Tamberi S.,
Spreafico A., Lombardo L., Gregorc V., Toschi L., Calandri C.,
Villa E., Crinò L.
Br J Cancer 2004 jan 12;90(1) 82-6
24 Kit expression in small cell lung carcinomas of the lung:effects
of chemotherapy.
Rossi G., Cavazza A., Marchioni A., Migali M., Bavieri M.,
Faccialongo N., Petruzzelli S., Longo L., Tamberi S.,
Crinò L. Mod Pathos 2003 16(10): 1041-7
25 Liver metastasesfrom rectal carcinoma:disease progression durino
chemotherapy despite loss of arterial phase hypervascularity on
real time contrast-enhanced harmonic sonographyat low acoustic
energy.
Piscaglia F., Gaiani S., Tamberi S., Celli N,
Cecilioni L., Gramantieri L., Bolondi L.
J Clin Ultrasound 2003 31(7: 387-91
26 Delayed emessi: incidence, pattern, prognostic factors and
optimal treatment.
Roila F., Donati D., Tamberi S., Margotti
G.
Support Care Cancer 2002 10(2):88-95
27 Treatment of stage IV colorectal carcinoma in elderly
patients
LM Pasetto, Tamberi S., Rossi E., Paris KM.,
Monfardini S. Critical review in oncology(Haematology 2005
54:145-155
28 Loss of kit expression after chemotherapy in small cell lung
cancer: therapeutic implications.
Tamberi S
., et al. Proc ASCO 2003 abstr. 2607 POSTER session
29 Cisplatin and etoposide followed by concurrent chemo-radiation
therapy in limited stage small cell lung cancer.
Benedetti G., Fedele M., Tamberi S., et al
J Clin Oncol 2005 23; 16S, 704
30 Analysis of neuroendocrine signal transduction and adhesion
proteins in SCLC tissue to predict the tumor response and the
progression free survival (PFS) in limited stage SCLC patients
subjected to chemo-radiation therapy
Benedetti G, …Tamberi S et al
J Clin Oncol 2006 abstr17075
31 Weekly irinotecan and infusional 5 fluorouracil in advanced
gastric cancer
Tamberi S et al
Proc GI cancer Symposium ASCO abstr 83 Poster selection
2006
32 Large cell neuroendocrine carcinoma of the lung. A
clinicopathologic and immunohistochemical study of 96 cases
with particular interest on the expression of targeted tyrosine
kinases Kit, PDGFR alpha and beta and Met
2004 ASCO
Annual Meeting Abstract No: 7032 First
Author:
S.
Tamberi
33 EGFR and
KRAS mutationsalong the spectrum of pulomnary epithelial tumors of
the lung and elaboration of a combined clinico pathologic and
molecular scorino system to predict responsiveness to EGFR
inihibitors Am J
Clin Path 2008
34
Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors,
EGFR and K-Ras mutations and differential diagnosis.
Rossi G, Sartori G, Cavazza A,
Tamberi S Lung Cancer 2008
Carboplatin
plus paclitaxel versus carboplatin plus pegylated liposomal
doxorubicin as first-line treatment for patients with ovarian
cancer: the MITO-2 randomized phase III trial.
Pignata S, Scambia
G, Ferrandina G, Savarese A, Sorio R, Breda E, Gebbia V, Musso P,
Frigerio L, Del Medico P, Lombardi AV, Febbraro A, Scollo P, Ferro
A, Tamberi S, Brandes A, Ravaioli A, Valerio MR, Aitini E, Natale
D, Scaltriti L, Greggi S, Pisano C, Lorusso D, Salutari V, Legge F,
Di Maio M, Morabito A, Gallo C, Perrone F.
J Clin Oncol. 2011
Sep 20;29(27):3628-35
Quality of life
analysis of TORCH, a randomized trial testing first-line erlotinib
followed by second-line cisplatin/gemcitabine chemotherapy in
advanced non-small-cell lung cancer.
Di Maio M, Leighl
NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V,
Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S,
Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni
V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS,
Signoriello S, Perrone F, Gridelli C; TORCH
Investigators.
J Thorac Oncol.
2012 Dec;7(12):1830-44
First-line
erlotinib followed by second-line cisplatin-gemcitabine
chemotherapy in advanced non-small-cell lung cancer: the TORCH
randomized trial.
Gridelli C,
Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P,
Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R,
Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F,
Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G,
Piccirillo MC, Di Maio M, Morabito A, Perrone F.
J Clin Oncol. 2012
Aug 20;30(24):3002-11
Ha svolto in piena autonomia ruolo di Pricipal Investigator
di studi in Good Clinical Practice (GCP) di studi internazionali in
particolare in ambito ginecologico (studio MIMOSA e attualmente due
studi del Gynecologic Cancer Intergroup) e in ambito di patologi
agastro intestinale (studio STAR, studio ITACAS, studi del gruppo
GISCAD etc).
E' inoltre membero del Guppo MITO, GISCAD e GIM di ricerca
nazionali.
